Fact CheckerSign in

NCT06120283RecruitingPhase 1

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Source: EU CTIS (euclinicaltrials.eu) · Last updated 1 Jun 2026

Status (registry)
Recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
91 (estimated)
First submitted
1 Nov 2023
Start date
22 May 2024
Lead sponsor
BeOne Medicines AG
EU CT number
2023-506888-34-00

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 91
  • 8 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.

Sites (8)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Institut Bergonie
Coordinator of this site? Confirm its status		BordeauxFranceRecruiting
Centre Francois Baclesse
Coordinator of this site? Confirm its status		Caen Cedex 5FranceRecruiting
Centre Oscar Lambret
Coordinator of this site? Confirm its status		LilleFranceRecruiting
Institut Paoli-Calmettes
Coordinator of this site? Confirm its status		MarseilleFranceRecruiting
Institut Curie
Coordinator of this site? Confirm its status		ParisFranceRecruiting
Centre De Lutte Contre Le Cancer Eugene Marquis
Coordinator of this site? Confirm its status		Rennes CedexFranceRecruiting
Institut De Cancerologie De L Ouest
Coordinator of this site? Confirm its status		St HerblainFranceRecruiting
Institut Gustave Roussy
Coordinator of this site? Confirm its status		VillejuifFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.